Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 2

Status

Completed 4Unknown 2

Sponsor Class

OTHER 6

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 6

Conditions

Stomach Neoplasms 23Colorectal Neoplasms 11Colonic Neoplasms 8Carcinoma, Hepatocellular 6Rectal Neoplasms 5Pancreatic Neoplasms 5Esophageal Squamous Cell Carcinoma 4Carcinoma, Non-Small-Cell Lung 4Breast Neoplasms 4Unspecified Adult Solid Tumor, Protocol Specific 3Squamous Cell Carcinoma of Head and Neck 3Head and Neck Neoplasms 3Esophageal Neoplasms 3Biliary Tract Neoplasms 3HER2-positive Gastric Cancer 2Gallbladder Neoplasms 2Uterine Cervical Neoplasms 1Stage IA Pancreatic Adenocarcinoma 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Malignant Neoplasms of Digestive Organs 1Lung Neoplasms 1Klatskin Tumor 1Immunotherapy 1Gastric Adenocarcinoma 1Fruquintinib 1For Patients With Colorectal Cancer Liver Metastases Who Were Not Able to Curative Surgical Resection.Focused on the Treatment Effect With the Quintuple Method 1Extrapancreatic Neuroendocrine Tumor 1Epstein-Barr Virus Infections 1Efficacy and Safety 1

Interventions

Sorafenib 202lenvatinib 129Bevacizumab 124Nivolumab 85pembrolizumab 72atezolizumab 72Radiosurgery 71durvalumab 63Oxaliplatin 59sintilimab 57Fluorouracil 54Doxorubicin 44tislelizumab 43apatinib 43Leucovorin 40tremelimumab 37camrelizumab 37Radiofrequency Ablation 37Radiotherapy 36Magnetic Resonance Spectroscopy 32Capecitabine 30regorafenib 29Folfox protocol 29Cisplatin 28cabozantinib 26Hepatectomy 26Gemcitabine 26Cyclophosphamide 26Ipilimumab 25toripalimab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Hepatocellular × Tegafur × Clear all
NCT03175679 2024-09-19

Adoptive Transfer of iNKT Cells for Treating Patients With Relapsed/Advanced HCC

Beijing YouAn Hospital

Phase 1 Completed
10 enrolled 14 charts
Gastrointestinal

Carcinoma, Hepatocellular

NCT03175705 2018-01-18

Adoptive Transfer of Specific HCC Antigens CD8+ T Cells for Treating Patients With Relapsed/Advanced HCC

Beijing YouAn Hospital

Phase 1 Unknown
18 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT02447679 2017-02-07

Oral Thalidomide and Tegafur-uracil to Decrease Hepatocellular Carcinoma Recurrence

Chang Gung Memorial Hospital

Phase 2 Completed
40 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Drug-Related Side Effects and Adverse Reactions

NCT00519688 2011-10-17

UFUR Plus Thalidomide for Advanced Hepatocellular Carcinoma

National Taiwan University Hospital

Phase 2 Completed
44 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT00464919 2009-07-07

Sorafenib Plus Tegafur/Uracil (UFUR®) for Hepatocellular Carcinoma (HCC)

National Taiwan University Hospital

Phase 2 Completed
50 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT00384800 2009-02-09

A Phase II Study of Tegafur/Uracil (UFUR®)Plus Thalidomide for the Treatment of Advanced or Metastatic Hepatocellular Carcinoma (HCC)

Far Eastern Memorial Hospital

Phase 2 Unknown
41 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡